KR20180048992A - T 세포 요법에 의해 다발성 골수종 및 형질 세포성 백혈병을 치료하는 방법 - Google Patents

T 세포 요법에 의해 다발성 골수종 및 형질 세포성 백혈병을 치료하는 방법 Download PDF

Info

Publication number
KR20180048992A
KR20180048992A KR1020187009368A KR20187009368A KR20180048992A KR 20180048992 A KR20180048992 A KR 20180048992A KR 1020187009368 A KR1020187009368 A KR 1020187009368A KR 20187009368 A KR20187009368 A KR 20187009368A KR 20180048992 A KR20180048992 A KR 20180048992A
Authority
KR
South Korea
Prior art keywords
allogeneic
cells
population
cell
human patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020187009368A
Other languages
English (en)
Korean (ko)
Inventor
겐터 코네
Original Assignee
메모리얼 슬로안-케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안-케터링 캔서 센터 filed Critical 메모리얼 슬로안-케터링 캔서 센터
Publication of KR20180048992A publication Critical patent/KR20180048992A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187009368A 2015-09-10 2016-09-09 T 세포 요법에 의해 다발성 골수종 및 형질 세포성 백혈병을 치료하는 방법 Withdrawn KR20180048992A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US62/216,525 2015-09-10
US201562220641P 2015-09-18 2015-09-18
US62/220,641 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (1)

Publication Number Publication Date
KR20180048992A true KR20180048992A (ko) 2018-05-10

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187009368A Withdrawn KR20180048992A (ko) 2015-09-10 2016-09-09 T 세포 요법에 의해 다발성 골수종 및 형질 세포성 백혈병을 치료하는 방법

Country Status (14)

Country Link
US (1) US20190381098A1 (https=)
EP (1) EP3347028A1 (https=)
JP (1) JP6947720B2 (https=)
KR (1) KR20180048992A (https=)
CN (1) CN108348552A (https=)
AU (1) AU2016320877A1 (https=)
CA (1) CA2997757A1 (https=)
HK (1) HK1257882A1 (https=)
IL (1) IL257929B2 (https=)
MX (1) MX395106B (https=)
RU (1) RU2743381C2 (https=)
TW (1) TWI759270B (https=)
WO (1) WO2017044678A1 (https=)
ZA (1) ZA201801656B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
US20210000874A1 (en) 2018-03-14 2021-01-07 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1560078B (zh) * 1998-07-31 2011-06-22 株式会社国际癌症免疫研究所 基于癌抑制基因wt1的产物的癌抗原
ATE399179T1 (de) * 1998-09-30 2008-07-15 Corixa Corp Zusammensetzungen und verfahren für wt1- spezifische immunotherapie
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
EP2365823B1 (en) * 2008-10-30 2016-11-30 Yeda Research And Development Company Ltd. Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment
CA2861206C (en) * 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
CN108348552A (zh) 2018-07-31
TWI759270B (zh) 2022-04-01
IL257929B1 (en) 2024-02-01
WO2017044678A1 (en) 2017-03-16
HK1257882A1 (zh) 2019-11-01
IL257929B2 (en) 2024-06-01
EP3347028A1 (en) 2018-07-18
US20190381098A1 (en) 2019-12-19
ZA201801656B (en) 2022-12-21
TW201714619A (zh) 2017-05-01
RU2018112526A (ru) 2019-10-10
JP2018530534A (ja) 2018-10-18
RU2743381C2 (ru) 2021-02-17
MX395106B (es) 2025-03-21
IL257929A (en) 2018-05-31
JP6947720B2 (ja) 2021-10-13
CA2997757A1 (en) 2017-03-16
AU2016320877A1 (en) 2018-04-19
MX2018002816A (es) 2018-06-08
RU2018112526A3 (https=) 2020-01-31

Similar Documents

Publication Publication Date Title
US20230002730A1 (en) Improved targeted t-cell therapy
US10577586B2 (en) Compositions and methods for modulating an immune response
CN103930130B (zh) 抗第三方中央型记忆t细胞、其产生方法以及其在移植和疾病治疗中的应用
JP5525689B2 (ja) 過剰増殖性障害を処置するための組成物および方法
JP2010516772A (ja) 免疫機能を調節する方法
BRPI0815578B1 (pt) peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
RU2743381C2 (ru) Способы лечения множественной миеломы и плазмоклеточного лейкоза посредством т-клеточной терапии
US20210213066A1 (en) Improved cell therapy compositions for hematopoietic stem cell transplant patients
AU2023221021B2 (en) Compositions and methods for antigen-specific t cell expansion
CA3126066A1 (en) Ex vivo activated t-lymphocytic compositions and methods of using the same
KR20180003575A (ko) T 세포 요법에 의한 엡스타인-바 바이러스 관련 림프증식성 장애의 치료 방법
Tanaka et al. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome
Amoozgar et al. Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells
EP3765602A1 (en) Methods of selecting t cell line for adoptive cellular therapy
US20160375060A1 (en) Methods of Treating Glioblastoma Multiforme by T Cell Therapy
US20240400992A1 (en) Compositions and methods for antigen-specific t cell expansion
Tentori et al. Antitumor and antimetastatic effects of dacarbazine combined with cyclophosphamide and interleukin-2 in Lewis lung carcinoma (3LL)
WO2026030538A1 (en) Cd84+/mertk+ myeloid derived suppressor cells and methods of use for transplantation tolerance
US20210393683A1 (en) Methods of managing tumor flare in adoptive immunotherapy
HK40050731A (en) Improved targeted t-cell therapy

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PC1202 Submission of document of withdrawal before decision of registration

St.27 status event code: N-1-6-B10-B11-nap-PC1202

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000